- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Romiplostim Biosimilar to Begin Comparative Clinical Trials in 2019
Finnish-based biosimilar developer, Paras Biopharmaceuticals Finland Oy, said this week that it is ready to begin testing its potential romiplostim biosimilar in clinical trials.
Finnish-based biosimilar developer, Paras Biopharmaceuticals Finland Oy, announced this week that it is ready to begin testing its potential romiplostim biosimilar in clinical trials.
Romiplostim, sold as NPlate, is indicated for the treatment of thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura (ITP). ITP is a blood disorder that causes the destruction of and impairs production of platelets.
The rareness of the disease would potentially qualify the drug as an Orphan Drug, a designation reserved for treatments of diseases that affect less than 200,000 people. In the United States, ITP has a prevalence of 9.5 cases per 100,000 adults. In children, this number falls to 5.3 per 100,000.
The company hopes to begin comparative clinical trials of the romiplostim biosimilar in 2019.
“The company is evaluating completed batches to assess comparability and looks forward to finalizing this work in the anticipation of supporting clinical trials and approvals for commercial supply on patent expiry in Europe and USA,” said Mark Jackson, MD, research and administration group, Paras Biopharmaceuticals.
According to Paras, the global occurrence of ITP is increasing. Due to small patient size and high production costs, yearly ITP treatment in the United States can cost up to $55,250 per year for each ITP patient. Paras hopes to provide an affordable healthcare option to patients with ITP.
Paras currently has 8 other biosimilars in development for the treatment of various disease states, including osteoporosis, rheumatoid arthritis, metabolic diseases, and oncology.
“The development and implementation of this commercial-scale manufacturing process for romiplostim is not only good news for the company but the wider healthcare environment,” said Ashesh Kumar, MD, Paras’ chief executive officer and director, biologics and licensing.
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
January 10th 2024IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.
Samsung Bioepis' Eculizumab Biosimilar Approved in Europe
May 31st 2023The European Commission has granted marketing authorization to Samsung Bioepis' biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, is the first hematology biosimilar from Samsung Bioepis to be approved in the European Union.
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points
August 24th 2022Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
